MCL1 and acute myeloid leukemia: Therefore, the ROS-NOXA-MCL-1 axis in response to VK2 appears to be attributed to VEN sensitization in AML cells, which appears to be the underlying molecular mechanism of the high response rate in our clinical outcomes (Table 2, Fig 1).